Q2 2023 Earnings Presentation

Strategic capital allocation framework Capital deployed over last 3 years (through December 31, 2022) Strategic Growth Priorities Reinvest for growth Reinvest in product development for high-return organic growth 7-8% of revenue invested in R&D 30% $2.6B 43% 27% Pursue M&A • Actively evaluate potential acquisitions Pursue targets aligned with long-term strategic goals and financial objectives Support dividends • Regular return of cash to shareholders through dividend at a level that is meaningful and sustained • Opportunistic repurchase of shares Current program suspended following recent acquisitions ■ Reinvest in R&D ■ M&A ■ Dividends ■ Share repurchase (A) Capital Returns to Shareholders Opportunistically repurchase shares Disciplined focus on ROIC and delivering total return (A): ResMed has not repurchased shares during the 3-year period ended December 31, 2022 11 © 2023 ResMed | Q2 2023 Earnings Presentation - Jan. 26, 2023 ResMed

View entire presentation